KeyCorp Research Analysts Lift Earnings Estimates for AngioDynamics, Inc. (ANGO)

AngioDynamics, Inc. (NASDAQ:ANGO) – Research analysts at KeyCorp lifted their Q3 2018 earnings estimates for shares of AngioDynamics in a research report issued on Thursday. KeyCorp analyst M. Mishan now anticipates that the medical instruments supplier will earn $0.20 per share for the quarter, up from their previous estimate of $0.18. KeyCorp has a “Hold” rating on the stock. KeyCorp also issued estimates for AngioDynamics’ Q4 2018 earnings at $0.26 EPS, FY2018 earnings at $0.75 EPS and FY2019 earnings at $0.91 EPS.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.16. The company had revenue of $86.70 million during the quarter, compared to the consensus estimate of $88.15 million. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. AngioDynamics’s revenue was down 2.6% on a year-over-year basis. During the same period last year, the company earned $0.19 earnings per share.

A number of other brokerages also recently issued reports on ANGO. Zacks Investment Research upgraded AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Tuesday, October 3rd. Canaccord Genuity restated a “hold” rating and issued a $17.00 price target on shares of AngioDynamics in a research report on Sunday, October 8th. TheStreet downgraded AngioDynamics from a “b-” rating to a “c” rating in a research report on Tuesday, January 2nd. BidaskClub downgraded AngioDynamics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Craig Hallum downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $18.40.

Shares of AngioDynamics (ANGO) traded down $0.25 on Monday, reaching $16.40. The company had a trading volume of 230,100 shares, compared to its average volume of 416,867. The company has a market capitalization of $611.32, a P/E ratio of -60.74, a PEG ratio of 1.57 and a beta of 1.04. AngioDynamics has a 12 month low of $14.80 and a 12 month high of $18.85. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.65 and a current ratio of 2.56.

A number of institutional investors and hedge funds have recently bought and sold shares of ANGO. SG Americas Securities LLC purchased a new position in AngioDynamics in the third quarter valued at about $143,000. Acrospire Investment Management LLC grew its stake in shares of AngioDynamics by 3.7% during the second quarter. Acrospire Investment Management LLC now owns 8,915 shares of the medical instruments supplier’s stock worth $145,000 after acquiring an additional 317 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of AngioDynamics during the third quarter worth about $175,000. Teachers Retirement System of The State of Kentucky grew its stake in shares of AngioDynamics by 54.9% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 11,000 shares of the medical instruments supplier’s stock worth $178,000 after acquiring an additional 3,900 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its stake in shares of AngioDynamics by 49.3% during the second quarter. BNP Paribas Arbitrage SA now owns 14,135 shares of the medical instruments supplier’s stock worth $229,000 after acquiring an additional 4,668 shares during the last quarter. Institutional investors own 95.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.com-unik.info/2018/01/10/keycorp-research-analysts-lift-earnings-estimates-for-angiodynamics-inc-ango.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit